Aurora Cannabis forms a supply agreement with SNDL.
Image | adobe.stock/The Allery
Aurora Cannabis announced in a recent press release (1), that the company was joining with SNDL Inc. (SNDL) in a supply agreement. Through this agreement, SNDL will be providing cannabis flower product that has been cultivated at the company’s indoor facility located in Atholville, New Brunswick, Canada, to Aurora Cannabis.
The press release mentioned that the supply agreement between Aurora Cannabis and SNDL is in place for three years with the additional option to expand the term length. The supply agreement is valued at $27 million, and both companies have worked together to manufacture other cannabis products and materials (1).
“Following our strong, third quarter performance driven by record setting growth in our international medical cannabis segment, Aurora remains focused on a balanced approach to operating a hybrid manufacturing network of in-house and third-party cultivation. We value our relationship with SNDL and their shared commitment to cultivation excellence,” said Miguel Martin, Executive Chairman and Chief Executive Officer of Aurora Cannabis.
“As Canada's leading integrated cannabis company, SNDL is well positioned as a supplier of quality cannabis products to commercial partners like Aurora. We have a shared approach to quality and cultivation excellence and look forward to expanding this relationship further,” said Zach George, Chief Executive Officer of SNDL.
Aside from this supply agreement, Aurora Cannabis partnered with Erfurt University of Applied Sciences in Leuna, Germany to form a student internship program with the school for medical cannabis cultivation (2).
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.